Renewable Energy Stocks Trading Alert; BIOX (BX.TO) Up Over 38%

Point Roberts WA- Aug. 10, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, issues a trading alert for BIOX CORPORATION (Toronto: BX.TO), a renewable energy company that designs, builds, owns and operates biodiesel production facilities.  The stock is trading up over 38% on light volume.



About BIOX Corporation
BIOX is a renewable energy company that designs, builds, owns and operates biodiesel production facilities. BIOX currently owns and operates a biodiesel production facility in Hamilton, Ontario, Canada with a nameplate capacity of 67 million litres per year. BIOX has an innovative, proprietary and patented production process that is capable of producing the highest quality, renewable, clean burning and biodegradable biodiesel fuel utilizing a variety of feedstocks - from pure seed oils to animal fats to recovered vegetable oils with no change to the production process. BIOX's high quality biodiesel fuel meets North American (ASTM D-6751) quality standards. BIOX is Canada's largest biodiesel producer and is focused on building, owning and operating a network of commercial scale biodiesel production facilities in jurisdictions where clearly defined renewable fuel standards policies exist.

About Investorideas.com – a leader in cleantech investor research
Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.

Visit our green and renewable showcase stocks and more investor research in the sector: http://www.investorideas.com/Companies/RenewableEnergy/  or
www.renewableenergystocks.com

Visit the renewable energy stocks directory – over 1300 green stocks on global stock exchanges  
http://www.investorideas.com/Companies/RenewableEnergy/Stock_List.asp


Investors - sign up for free green stocks trading alerts and news
http://www.investorideas.com/Resources/Newsletter.asp

Follow Renewable Energy Stocks on Facebook.com
http://www.facebook.com/renewableenergystocks

Disclaimer/ Disclosure: The following news is part of the Clean Wind Energy Tower, Inc. (OTCBB: CWET) advertising program with Investorideas.com. Clean Wind Energy, Inc.  Compensates investorideas.com (one thousand five hundred per month, 100,000 144 shares) to be showcased as a renewable energy stock within its hub of sites and blogs.Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and its management and is not the opinion of Investorideas.com. Learn more: www.InvestorIdeas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Investorideas.com was not compensated by BIOX CORPORATION (Toronto: BX.TO)

For more information about Investorideas.com contact:
800.665.0411, Email: dvanzant@investorideas.com or cvanzant@investorideas.com

Biotech/Pharma Stocks Trading News: AEMD, ANX, OXGN, CHTP, EXEL

Navigating the Biotech Sector in a Volatile Market

Point Roberts, WA- Aug 10, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for biotech and pharma stocks trading August 9th. Yesterday’s trading session saw gains for investors in a very volatile global market.  As investors navigate this market, there are still profits to be made in all sectors.   

Aethlon Medical (OTCBB: AEMD), a pioneer in developing therapeutic filtration devices, traded relatively flat yesterday and is seeing gains in morning trading today, August 10th.   The stock is trading at $0.0839, up 0.0049 (6.20%) .

The company recently introduced  the Aethlon ADAPT™ (Adaptive Dialysis-Like Affinity Platform Technology) system, as an innovative medical device platform that provides a basis to create new therapeutic devices through the convergence of affinity drug agents and plasma membrane technologies.  The Aethlon ADAPT™ system provides a previously unrecognized commercialization pathway to antibody and other affinity drug developers, who should also appreciate a less onerous medical device regulatory pathway.  We are already seeing evidence of our ADAPT™ system being the impetus for industry collaborations that offer new channels of early revenue generation.  

In yesterday’s session, OXiGENE, Inc. (NASDAQ:OXGN) gained 0.44 (39.64%) to $1.55 as the stock has slumped about 60% in the past one week. The stock made its new 52-week low of $1.08 on Monday. The stock is down 68% so far this year.

ADVENTRX Pharmaceuticals, Inc. (AMEX:ANX) shares also climbed 0.45 (21.53%) to $2.54 after it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for Exelbine™ (vinorelbine injectable emulsion) for the treatment of non-small cell lung cancer.  

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) climbed 0.72 (20.22%) to $4.28 after it has successfully reached its target enrollment of 120 patients in its Phase II trial of droxidopa for the treatment of fibromyalgia. Top-line results of the trial are expected by the end of the year.

Exelixis, Inc. (NASDAQ:EXEL) added 1.07 (17.95%) to $7.03. Last week, the company reported a loss of 16 cents a share on revenue of $32.2 million, better than analysts’ estimates of a loss of 17 cents a share on revenue of $37.47 million.

The company sees FY2011 revenue of $220-$250 million, versus prior guidance of $145-$160 million and the consensus of $166.3 million.


Biotech Medical Company Snapshot for Aethlon Medical (OTCBB: AEMD)

Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD

Get biotech news and stock alerts  
http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp


At Aethlon Medical, we create revolutionary devices to address infectious disease and cancer. Our devices are designed to be novel platform solutions that fill therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier® is the first medical device to selectively target the removal of infectious viruses and immunosuppressive proteins from the entire circulatory system. We recently discovered that our Hemopurifier® captures tumor-secreted exosomes that suppress the immune system of those afflicted with cancer. Prior to this discovery, a therapeutic strategy to directly inhibit or reverse the immunosuppressive destruction caused by exosomes did not exist in cancer care. By eliminating this mechanism, we believe our Hemopurifier® can fill an unmet clinical need and provide the benefit of an immune-based therapy without adding drug toxicity or interaction risks to established and emerging treatment strategies.

Human studies have documented the ability of our Hemopurifier® to safely reduce viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV) infected patients without the administration of antiviral drugs.  However, our initial clinical and commercialization focus is to establish our Hemopurifier® as an adjunct therapy to enhance the benefit of both infectious disease and cancer treatment regimens. In this regard, we plan to commercialize our Hemopurifier® in India as we advance our clinical strategies in the United States and the European Union.  In vitro studies conducted by government and non-government research institutes have also verified that our Hemopurifier® has broad-spectrum capabilities against bioterror and emerging pandemic threats. These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier® provides us with a pipeline into four significant market opportunities:
1.Cancer: A treatment candidate to improve patient responsiveness to established cancer therapies by removing immunosuppressive exosomes from circulation.
2.Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction at the outset of standard of care drug regimens.   
3.Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
4.Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discovery of biomarkers that allow doctors to optimize patient therapy. Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.  Such potential risks and uncertainties include, without limitation, the company's ability to commercialize its Hemopurifier® in India, capability of the Hemopurifier® to reduce viral loads and other disease conditions or to identify or treat disease conditions such as cancer or Hepatitis-C, including the ability to capture exosomes and the impact that potential ability may have on disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

Contacts:  
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, including biotech stocks

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech,  biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011       
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

800-665-0411 - cvanzant@investorideas.com
Source - Investorideas.com

Tech Trading Alert; Nyxio Technologies (OTC.BB: NYXO) Moves on News Unveiling First Fully Integrated Smart TV with Built-In PC

POINT ROBERTS, Aug. 10, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues a trading alert for Nyxio Technologies Corporation (OTC.BB: NYXO). The stock traded 907,788 shares, closing at $0.53, up .06 or 12.77% yesterday and continues its gains in morning trading.

The company reported it had launched the VioSphere Smart TV, the first -- and only -- fully integrated television with a built-in personal computer on the market today. Designed as a full-spectrum entertainment system, the touch-screen TV combines HDTV technology with a personal computer and media center. The latest product from Nyxio, the VioSphere Smart TV, saves time, money, space and energy.

The VioSphere Smart TV centers on a fully integrated touch-screen TV. Integrated components include a DVD player/burner, Bluetooth, Wi-Fi, webcam and, of course, a PC. A split-screen design allows for experiencing content via television while viewing content from the PC simultaneously. Touch-screen navigation enables users to move through applications and features easily. Additionally, the VioSphere Smart TV offers video conferencing capabilities, which extends its use from home to the professional setting.





About Nyxio Technologies Corporation (OTCBB: NYXO)

Visit the company profile at Investorideas.com
http://www.investorideas.com/CO/NYXO/

Request news or alerts on Nyxio Technologies Corporation (OTCBB: NYXO)
http://www.investorideas.com/Resources/Newsletter.asp


Nyxio Technologies was established in 2007 to deliver high-quality, cutting-edge products to the consumer electronics industry. Nyxio identifies gaps in the market and develops creative products to fill those voids, such as with the world's first integrated flat screen TV and full PC, the VioSphere Smart TV. In addition, by consolidating key hardware into more efficient devices, Nyxio not only reduces the overall environmental footprint of end users, but keeps products reasonably priced. Headquartered in Portland, OR, Nyxio Technologies is a publicly traded company with more than 15 knowledgeable employees. For more information visit: www.nyxio.com.

INVESTOR RELATIONS
Summit IR Services, Inc.
Phone: 1-855-436-6996 (NYXO)
info@nyxiotech.com
www.nyxio.com

Investorideas.com Free Investor Tools;

Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp

Join Investor Ideas – Research renewable energy stocks, mining, oil and gas, agriculture stocks, cloud computing stocks and more…   
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only stock directories in leading sectors including renewable energy, water and energy stocks. Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/


About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook   http://www.facebook.com/Investorideas

Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. NYXO is a paid advertising showcase company on Investorideas.com – three thousand per month
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
www.InvestorIdeas.com/About/Disclaimer.asp


Contact Investorideas.com
800-665-0411 – cvanzant@investorideas.com
Source – Investorideas.com
Retails Companies Reporting Same-Store Sales (ZUMZ, HOTT, M, LTD, CATO)
Retail Stocks In Focus (DDS, JCP, KSS, JWN, ROST)
Top Gainers (APAC, MCZ, OCZ, RENN, PMI)
Top Losers (AFFX, LL, FST, YMI, AIB)
Stocks To Watch (TGT, REDF, DANG, MOBI, SODA)

Tuesday's Top Gainers on NASDAQ: FRP, MAKO, LMNX, SYNM

POINT ROBERTS - August 10, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, reports on top percentage gainers on the NASDAQ for Aug. 08, 2011. FairPoint Communications was the notable winner in yesterday’s sessions with the stock gaining 44.32%.

FairPoint Communications, Inc. (NASDAQ:FRP) soared 2.03 (44.32%) to $6.61 after the company said that its net loss during the second quarter trimmed to $27.1 million versus $54.2 million a year earlier. Revenue during the quarter came at $262.6 million. High-speed Internet penetration increased to 28.3% of voice access lines at June 30, 2011.
MAKO Surgical Corp. (NASDAQ:MAKO) rose 7.47 (34.89%) to $28.88 after the company reported a loss of 24 cents a share on revenue of $18.6 million in its second quarter, ahead of analysts’ estimates of a loss of 24 cents a share on revenue of $16.07 million.
Luminex Corporation (NASDAQ:LMNX) increased 6.12 (33.08%) to $24.62 after the company reported $4.6 million or $0.11 a share on revenue of $47.64 million in its second quarter, ahead of analysts’ estimates of $0.06 per share on revenue of $40.67 million.
Looking forward, the company raised its 2011 annual revenue guidance to a range of $180 million to $185 million from its prior guidance of $163 million to $170 million. Analysts currently expect the company to post revenue of $170.58 million for the full year 2011.
Syntroleum Corp (NASDAQ:SYNM) moved 1.87 (13.09%) to 0.26 (25.00%) after the company announced record renewable fuels production and financial results for the six months ended June 30, 2011.
For the six months ended June 30, 2011, the company reported an operating loss of $1.8 million resulting from total revenues of $2.0 and operating expenses of $3.8 million.
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Research renewable energy stocks, mining, oil and gas, agriculture stocks, cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only stock directories in leading sectors including renewable energy, water and energy stocks. The renewable energy stocks directory now has over 1300 global green stocks listed - it’s the largest online!
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com

Biotech and Pharma Investor Alert; BioSante (NASDAQ: BPAX) Rebounds, Trading up over 14%

Point Roberts, WA, LINCOLNSHIRE, Ill –August 9, 2011,– Investorideas.com, a leader in sector stock research for independent investors , issues a trading alert for specialty biotech/pharma stock, BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for  August 9th. The stock has bounced back as high as $2.37 in today’s trading.  BioSante (NASDAQ: BPAX) fell yesterday with the general market fear, following the US downgrade.



News Excerpt: Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals (NASDAQ: BPAX), Discusses the Future of LibiGel® Following Closing of $48 Million Offering
“ BioSante plans to use the net proceeds from the offering for general corporate purposes, including funding the ongoing Phase III clinical study program for LibiGel® for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).

BioSante Pharmaceuticals Interview

Q: Investorideas.com

Mr. Simes, following the closing of the $48 Million offering, you report use of proceeds will include ongoing Phase III clinical study program for LibiGel® for the treatment of female sexual dysfunction (FSD). How far will this take you into the study and what does this mean for investor confidence in taking this product to market?

A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals

The proceeds of the $48 million underwritten financing together with the cash we had before the transaction results in almost $80 million in cash. This cash balance is sufficient to fund the LibiGel program and BioSante through our anticipated LibiGel new drug application (NDA) submission by the end of 2012, and in fact all the way through a potential FDA approval which could come in mid-2013. This long runway was one of the key reasons for executing the transaction at this time. Another reason for executing the transaction at this time was so that in the fourth quarter of this year when we announce LibiGel efficacy data investors can concentrate on the quality of the data versus being concerned that we would need to raise money.”

About BioSante Pharmaceuticals, Inc.

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology.  BioSante’s lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).  BioSante’s first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante’s licensee.  BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials.  Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology.  Additional information is available online at: www.biosantepharma.com.

To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante’s plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions  and other statements identified by words such as “will,” “continue,” “could,”  “believe,” “intends,” “continue,” “expects,” “anticipates,” “estimates,” “may,” other words of similar meaning, derivations of such words or the use of future dates.  Forward-looking statements by their nature address matters that are, to different degrees, uncertain.  Uncertainties and risks may cause BioSante’s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements.  For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante’s licensees or sublicensees; the success of clinical testing; and BioSante’s need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante’s actual results are described in BioSante’s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q.  All forward-looking statements in this news release speak only as of the date of this news release.  BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact BioSante:
For info about BioSante Pharmaceuticals, Inc

For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com

For Media:
McKinney/Chicago
Alan Zachary
(312) 506-5220
azachary@mckinneychicago.com

BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com

Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks. Investorideas.com is known for its comprehensive stock directories in each sector and sector specific newswires.

Disclaimer: The following news/content is paid for as part of the  BPAX showcase program  (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  

Source: Investorideas.com, BioSante, Investorideas.com
Contact Investorideas.com

800 665 0411 cvanzant@investorideas.com

Omnicom Group Inc. (NYSE-OMC) - There's Something Smedley about it?

POINT ROBERTS - August 9, 2011 - www.InvestorIdeas.com, a global investor research portal for independent investors, issues an investor audio file for Omnicom Group Inc. (NYSE-OMC). There's something "Smedley" he knows the rest of the world doesn't get. We have researched the stock and we can't find what the "Smedely" referral is.

The following is a real message left on our answering machine at Investorideas.com On Friday.
With all the craziness in the market - I guess investors have gone crazy too.
We have never heard anything quite like this message left by an anonymous investor. So here it is, unedited and raw for your review. It was too good to keep to ourselves!
If you understand what he is talking about - contact your doctor immediately!
Listen to Audio file: click here
Omnicom Group Inc. (NYSE-OMC) (www.omnicomgroup.com) is a leading global marketing and corporate communications company. Omnicom’s branded networks and numerous specialty firms provide advertising, strategic media planning and buying, digital and interactive marketing, direct and promotional marketing, public relations and other specialty communications services to over 5,000 clients in more than 100 countries.
Investorideas.com Free Investor Tools;
Sign up for the free investor news and stock alerts in leading sectors! http://www.investorideas.com/Resources/Newsletter.asp
Join Investor Ideas - Research energy stocks, mining, agriculture stocks, cloud computing stocks and more…
Investorideas.com Members currently have 24/7 online access to the exclusive subscriber-only eleven stock directories in leading sectors including renewable energy, water and energy stocks.
Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising . www.InvestorIdeas.com/About/Disclaimer.asp
For Additional Information and or interest in becoming a content /revenue partner:
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.com
Source - Investorideas.com

Consumer/ Retail Stocks; YesDTC (OTCBB:YESD) Announces Name Change to MotorBooster, Inc. to Concentrate on High Growth Fuel Catalyst Market

SAN FRANCISCO - August 9, 2011 (Investorideas.com newswire) - YesDTC Holdings, Inc. (OTCBB:YESD), a direct-to-consumer marketer and global distributor of consumer goods and products, today announced the Company plans to change its name to MotorBooster, Inc. The change to MotorBooster, Inc. reflects the Company's intention to actively and exclusively pursue the marketing, distribution and sale of its MotorBooster(TM) combustion catalyst and engine conditioner as part of its nationwide product rollout.

Going forward, the Company has determined it will concentrate its corporate efforts on its unique, proprietary MotorBooster product, which is protected under U.S. patents and has received EPA Certification to not cause engine damage. Recent independent tests have shown the MotorBooster fuel catalyst formulation to generate a very significant 16% increase in fuel efficiency as well as substantial fuel emission reductions. In addition to these tests, the Company also recently announced the University of Alaska, Fairbanks, along with a major multinational oil company, will be jointly conducting extensive tests on MotorBooster for its potential to reduce emissions, improve fuel efficiency and enhance engine performance in the oil industry.
Joseph Noel, CEO of YesDTC, commented, "The results of the testing on MotorBooster thus far has been so dramatic and the possibilities for fuel savings across a multitude of industries so vast that the Company and Board of Directors believe the Company and its investors will be best served by focusing exclusively on this opportunity going forward." He continued, "By now, anyone following our story has already noted the 16% increase in fuel efficiency and substantial improvement in lowering fuel emissions that MotorBooster has been shown to demonstrate in independent dynamometer testing and we believe the upcoming tests at the University of Alaska will provide further validation of this amazing product's efficacy. In regards to the other product lines we have pursued, WordSmart in particular, while we believe they hold strong revenue possibilities, they pale in comparison to the huge market size and vast consumer interest we believe exists for MotorBooster. Going forward, we plan to devote our full corporate efforts to the promotion of MotorBooster, which we view as clearly holding the highest revenue and profit potential of any product we've encountered to date."
At a national average cost per gallon of $3.66 for regular gasoline, and $3.92 for premium, the Company estimates a 16% increase in fuel efficiency as demonstrated by its last independent test would mean a very significant nearly $0.59 savings per gallon on regular and a $0.63 savings on premium, while users switching from premium to regular as a result of using MotorBooster would realize even more significant savings at the pump. As an automotive combustion catalyst that targets the consumer market, MotorBooster is designed to increase fuel economy, reduce hydrocarbon emissions and enhance engine performance. MotorBooster(TM) is a proprietary formulation tablet that users simply insert into their gas tank, upon which it dissolves into the fuel to achieve mileage, emissions and enhancement benefits, including allowing motorists to use lower octane fuels for double-savings at the pump. MotorBooster is protected under U.S. patents and has received EPA Certification to not cause engine damage.
About YesDTC Holdings, Inc.
YesDTC Holdings, Inc. is a direct-to-consumer marketing company specializing in direct response television (DRTV), Internet and retail marketing programs. The Company brings a unique set of skills to this market space. YesDTC combines both the creative talents and financial acumen needed to create a total package for direct-to-consumer marketing programs. Importantly, the Company also maintains a strategic partnership with Schulberg Media Works (SMW), a pioneering media production firm in the direct-to-consumer space with a highly acclaimed list of successful client campaigns and product infomercials. The Company's infomercial for its MediPendant product can be seen at www.medipendant.com. Information on NutriFusion can be seen at www.nutrifusion.com and information about the Company's newest offering from Alo Networks can be found at http://www.alonetworks.com/. More information on YesDTC Holdings can be found at www.yesdtc.com.
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" that involve risks and uncertainties. These include statements about our expectations, plans, objectives, assumptions or future events. You should not place undue reliance on these forward-looking statements. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We undertake no obligation to publicly release revisions to these forward-looking statements to reflect future events or circumstances or reflect the occurrence of unanticipated events.
Contact:
YesDTC Holdings, Inc.
Christian Kirsebom
(925) 247-6666
Contact Investorideas.com
dvanzant@investorideas.com
Visit the YESD showcase profile at Investorideas.com
http://www.investorideas.com/CO/YESD/
Request News and Info on YESD
Disclosure, Disclaimer/ YESD is a paid advertising client on Investorideas.com.
YESD: one time fee of five thousand cash and three hundred thousand 144 shares
About Investorideas.com
- Investor Ideas the can change the world

Sign up for free stock alerts and news:
http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics
Investor Protection and Regulation for Pinks sheets: http://www.pinksheets.com/otcguide/investors_protection.jsp